NOV .2 0 2006

eby certify that this paper (along with any paper referred to as being attached enclosed) is being deposited with the U.S. Postal Service on the date shown flow with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O, Box 1450, Alexandria, VA 22313-1450.

Dated: November 9, 2006

(Katherine L. Neville)

Docket No.: 27866/39370A

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Darcey Clark et al.

Application No.: 10/572,543

Confirmation No.:

Filed: March 17, 2006

Art Unit:

For:

USE OF CHK1 INHIBITORS TO CONTROL

CELL PROLIFERATION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR §1.97(b)(3)).

In accordance with 37 CFR §1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR §1.98(a)(2).

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. In accordance with 37 CFR

941916

Application No.: 10/572,543 Docket No.: 27866/39370A

§1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 27866/39370A. A copy of this paper is enclosed.

Dated: November 9, 2006

Respectfully, submitted,

Katherine L. Neville

Registration No.: 53,379

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicant

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of - 4

Complete if Known				
10/572,543				
March 17, 2006				
Darcey Clark				
0				
Not Yet Assigned				
27866/39370A				
	10/572,543 March 17, 2006 Darcey Clark 0 Not Yet Assigned			

			U.S. PA	TENT DOCUMENTS	
Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*		Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	A1	US-20030069284-A1	04-10-2003	Keegan et al.	
	A2	US-20030162785-A1	08-28-2003	Lin et al.	
	A3	US-20030199511-A1	10-23-2003	Li et al.	,
	A4	US-20040014765-A1	01-22-2004	Boyle et al.	
	A5	US-20040092535-A1	05-13-2004	Barsanti et al.	
	A6	US-6,211,164	04-03-2001	Luo et al.	
	A7	US-6,495,586-A1	12-17-2002	Jacobs et al.	

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages		
Initials*	No.'	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T ⁶	
	B1	WO-98/53050					
	B2	WO-99/17769					
	B3	WO-00/16781					
	B4	WO-01/53268					
	B5	WO-01/53274					
	B6	WO-01/57206					
	B7	WO-US02/06452					
	B8	WO-02/070494					
	B9	WO-02/070515 ·					
	B10	WO-02/16326					
	B11	WO-03/004488					
	B12	WO-03/028724		,			
	B13	WO-03/028731					
	B14	WO-03/029241		•			
	B15	WO-03/029242					
	B16	WO-03/037886					
	B17	WO-03/051838					
	B18	WO-03/101444					
	B19	WO-04/018419					
	B20	WO-2002/070494					
	B21	WO-2003/091255					
	B22	WO-2004/014876					
	B23	WO-2004/048343					
	B24	WO-2004/063198					
	B25	WO-2006/014359		•			
	B26	WO-2006/021002					

xaminer	Date
Signature	
	Considered

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/572,543	
11	IFORMATION	I DI	SCLOSURE	Filing Date	March 17, 2006	
S	STATEMENT BY APPLICANT			First Named Inventor	Darcey Clark	
				Art Unit	0	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	2	of	4	Attorney Docket Number	27866/39370A	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	Ajiro et al., J. Biol. Chem., Vol. 271, pp.13197-13201 (1996).		
	C2	Andreaseen et al., Proc. Natl. Acad. Sci. (USA), Vol. 86, pp.2272-2276 (1992).		
	C3	Baker et al., Genes Dev., Vol. 8, pp.2416-2488 (1994).		Bake
	C4	Blasina et al., Curr. Biol., Vol. 9, pp.1-10 (1999).		
	C 5	Bracey et al., Clin. Cancer Res., Vol. 3, pp.1371-1381 (1997).		
	C6	Bradley et al., Clin. Cancer Res., Vol. 7, pp.3229 (2001).		
	C7	Bunz et al., Science, Vol. 282, pp.1497-1501 (1998).		
	C8	Carr, Science, Vol. 271, pp.314-315 (1996).		
	C9	Cerra et al., Methods in Cell Biology, Vol. 33, pp.1-12 (1990).		
	C10	Chen et al., Oncogene, Vol. 18, pp.249-256 (1999).		
	C11	Connell-Crowley et al., Mol. Biol. Cell, Vol. 8, pp.287-301 (1997).		
	C12	Fan et al., Cancer Res., Vol. 55, pp.1649-1654 (1995).		
	C13	Feijoo et al., J. Cel Biol., Vol. 154, pp.913-923 (2001).		
	C14	Furnari et al., Science, Vol. 277, pp.1495-1497 (1997).		
	C15	Gandhi et al., <i>J. Clin. Ocol.</i> , Vol. 20, pp.665-673 (2002).		
	C16	Gatei et al., J. Biol. Chem., Vol. 278, pp.14806-14811 (2003).		
	C17	Gesner, Abstract at SRI Conference: Protein Phosphorylation and Drug Discovery World Summit, (2003).		
	C18	Gijbels et al., Exp. Dermatol., Vol. 9, pp.351-358 (2000).		
	C19	Goto et al., J. Biol. Chem., Vol. 274, pp.25543-25549 (1999).		
	C20	Grant et al., Drug Resistance Updates, Vol. 6, pp.15-26 (2003).		
	C21	Guo et al., Genes Dev., Vol. 14, pp.2745-2756 (2000).		
	C22	Hartwell et al., Science, Vol. 246, pp.629-634 (1989).		
	C23	Hartwell et al., Science, Vol. 266, pp.1821-1828 (1994).		
	C24	Hirose et al., Cancer Res., Vol. 61, pp.5843-5849 (2001).		
	C25	Levine, Cell, Vol. 88, pp.3234-3331 (1997).		
	C26	Liu et al., Genes Dev., Vol. 14, pp.1448-1459 (2000).		
	C27	Lopez-Girona et al., Proc. Natl. Acad. Sci. (USA), Vol. 98, pp.11289-11294 (2001).		
	C28	Mack et al., Cancer Chemother Pharmacol., Vol. 51, No. 4, pp.337-348 (2003).		
	C29	Matsuoka et al., Science, Vol. 282, pp.1893-1897 (1998).		
	C30	Ng et al., J. Biol. Chem., Vol. 279, No. 10, pp.8808-8819 (2004).		
	C31	O'Connell et al., EMBO J., Vol. 16, pp.545-554 (1997).		
	C32	Sanchez et al., Science, Vol. 277, pp.1497-1501 (1997).		
	C33	Sanchez et al., Science, Vol. 286, pp.1166-1171 (1999).		
	C34	Schultz et al., J. Med. Chem., Vol. 42, No. 15, pp.2909-2919 (1999).		

Examiner Signature Date Considered

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/572,543 **Application Number** INFORMATION DISCLOSURE March 17, 2006 Filing Date STATEMENT BY APPLICANT Darcey Clark First Named Inventor Art Unit 0 (Use as many sheets as necessary) Not Yet Assigned **Examiner Name** 27866/39370A Sheet of Attorney Docket Number 4

C35	Sedlacek et al., Int. J. Oncol., Vol. 9, pp.1143-1168 (1996).	
C36	Shi et al., Cancer Res., Vol. 61, pp.1065-1072 (2001).	
C37	Sorensen et al., Cancer Cell, Vol. 3, No. 3, pp.247-258 (2003).	
C38	Stojic et al., Genes Dev., Vol. 18, No. 11, pp.1331-1344 (2004).	
C39	Tenzer et al., Curr. Med. Chem. Anti-Cancer Agents, Vol. 3, pp.35-46 (2003).	
C40	Wang et al., Natl. Acad. Sci. (USA), Vol. 100, No. 26, pp.15387-15392 (2003).	
C41	Weinberg, Cell, Vol. 81, pp.323-330 (1995).	
C42	Weinert et al., Genes and Devlopment, Vol. 8, pp.652 (1994).	
C43	Xiao et al., J. Biol. Chem., Vol. 278, No. 24, pp.21767-21773 (2003).	
C44	Yin et al., Biochem. Biophys. Res. Commun., Vol. 295, pp.435-444 (2002).	
C45	Zhao et al., Mol. Cell Biol., Vol. 21, pp.4129-4139 (2001).	
C46	Zhao et al., PNAS USA, Vol. 99, pp.14795-14800 (2002).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/92 (09-06)
Approved for use through 03/31/2007. OMB 0651-003
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/572,543

Attorney Docket No.: 27866/39370A

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

> MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	November 9, 2006 . Date	•
	Statt Z	viel
	Signatu	re
	Katherine L.	<u></u>
	Typed or printed name of per	son signing Certificate
	53,379	(312) 474-6632
Regi	istration Number, if applicable	Telephone Number
Note:	Each paper must have its own certificate of each submitted paper.	of mailing, or this certificate must identify
	IDS (Citation) by Applicant (70 Distora	

IDS (Citation) by Applicant (79 References) (4 pages)